Search for: "PAR PHARMACEUTICALS"
Results 121 - 140
of 303
Sort by Relevance
|
Sort by Date
25 Jun 2013, 9:51 am
Par Pharmaceutical backed Paddock by agreeing to share the patent litigation costs if it obtained approval for its generic product. [read post]
25 Jun 2013, 6:52 am
Soon after, two other companies, Actavis and Paddock (the latter in agreement with a third company, Par Pharmaceutical) had filed Abbreviated New Drug Applications for generic drugs modeled after AndroGel, declaring that Solvay’s patent 6,503,894 was invalid, under paragraph 4 of the Hatch-Waxman Act. [read post]
24 Jun 2013, 10:08 am
Par Pharmaceutical backed Paddock by agreeing to share the patent litigation costs if it obtained approval for its generic product. [read post]
24 Jun 2013, 6:08 am
Par Pharmaceutical backed Paddock by agreeing to share the patent litigation costs if it obtained approval for its generic product. [read post]
23 Jun 2013, 8:50 pm
• Defendants: Par Pharmaceutical Inc.; Actavis Elizabeth LLC; Actavis Inc. [read post]
21 May 2013, 2:26 pm
., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]
20 May 2013, 7:00 am
For all of this, the company pleaded guilty to producing sub-par products and making false statements to the FDA. [read post]
28 Apr 2013, 9:00 pm
Ces caractéristiques sont couramment utilisées dans la technique et donc compréhensibles par l'homme du métier. [read post]
11 Apr 2013, 4:57 am
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than $400 million. [read post]
5 Apr 2013, 2:59 am
” The AP continues, “Officials from Woodcliff Lake-based Par Pharmaceutical Cos. entered the pleas Tuesday in federal court in Newark, N.J., and agreed to pay a total of $45 million in fines. [read post]
3 Apr 2013, 6:19 pm
If the clinic is a Medicare par provider, they cannot balance bill, so their choice is to stop treating patients or take a loss. [read post]
2 Apr 2013, 2:48 pm
The post Par Pharmaceuticals Settles Civil and Criminal Off-Label Marketing Charges for $45 Million appeared first on Tycko & Zavareei LLP. [read post]
2 Apr 2013, 1:55 pm
Last month, Par Pharmaceutical Companies Inc. pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
11 Mar 2013, 8:12 am
New Jersey-based Par Pharmaceutical Companies Inc. [read post]
5 Mar 2013, 1:56 am
On March 5, the Department of Justice announced that generic drug maker Par Pharmaceuticals, Inc., entered a guilty plea and agreed to pay a combined $45 million to settle criminal and civil charges that it promoted Megace ES off-label. [read post]
25 Feb 2013, 11:29 am
In a world where privately funded studies in areas ranging from pharmaceuticals to finance to climate science have come into question, autonomous forms of knowledge have value. [read post]
11 Feb 2013, 6:00 am
Of course self-insured employers do not set out to get sub-par results from the adjusters. [read post]
7 Feb 2013, 10:50 am
Par Pharmaceutical, Inc., 694 F.3d 1344, 1351 (Fed. [read post]
15 Jan 2013, 11:33 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
